Congenital Heart Disease and Pulmonary Hypertension, Winter 2013 (Vol 11, No 4)
The mission of Advances in Pulmonary Hypertension is to serve as the premier forum for state of the art information regarding diagnosis, pathophysiology, and treatment of pulmonary hypertension. The 2008 Dana Point revision of the World Health Organization Classification serves as a guide to categories of pulmonary hypertension addressed in Advances in Pulmonary Hypertension. While focusing on on WHO Group I PAH, the other categories (Group II, pulmonary venous hypertension; Group III, associated with chronic lung disease and/or hypoxemia; Group IV, pulmonary embolic hypertension; Group V, miscellaneous) are also addressed. This mission is achieved by a combination of invited review articles, roundtable discussions with panels consisting of international experts in PH, and original contributions. In addition, a special section in selected issues entitled “Profiles in Pulmonary Hypertension” recognizes major contributors to the field and serves as an inspiring reminder of the rich and collegial history of dedication to advancing the field.